Loading...
XSTOVITR
Market cap2.55bUSD
Dec 20, Last price  
208.00SEK
1D
-2.62%
1Q
-14.33%
Jan 2017
168.73%
Name

Vitrolife AB

Chart & Performance

D1W1MN
XSTO:VITR chart
P/E
—
P/S
8.02
EPS
—
Div Yield, %
0.41%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
24.99%
Revenues
3.51b
+8.60%
103,855,000120,120,000171,264,000188,939,000225,141,000274,626,000297,565,000356,115,000362,020,000452,738,000510,512,000722,370,000856,106,0001,046,217,0001,151,348,0001,480,132,0001,245,572,0001,680,804,0003,234,000,0003,512,000,000
Net income
-3.85b
L
11,936,00014,859,00015,199,00036,057,00029,995,00034,114,00029,182,00030,360,000333,772,00056,274,000109,109,000182,845,000190,368,000263,640,000309,697,000382,785,000286,845,000341,000,000394,000,000-3,851,000,000
CFO
757m
+19.03%
14,005,00014,121,00023,784,00021,285,00042,793,00041,478,00048,399,00039,460,00059,930,000106,127,000145,666,000193,526,000181,262,000312,189,000349,435,000413,333,000356,448,000384,306,000636,000,000757,000,000
Dividend
Apr 26, 20241 SEK/sh
Earnings
Jan 30, 2025

Profile

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
URL
https://www.vitrolife.com/
IPO date
Jun 26, 2001
Employees
1,102
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,512,000
8.60%
3,234,000
92.41%
1,680,804
34.94%
Cost of revenue
2,879,000
2,599,000
1,252,905
Unusual Expense (Income)
NOPBT
633,000
635,000
427,899
NOPBT Margin
18.02%
19.64%
25.46%
Operating Taxes
139,000
143,000
116,405
Tax Rate
21.96%
22.52%
27.20%
NOPAT
494,000
492,000
311,494
Net income
(3,851,000)
-1,077.41%
394,000
15.54%
341,000
18.88%
Dividends
(115,000)
(109,000)
(86,799)
Dividend yield
0.44%
0.43%
0.14%
Proceeds from repurchase of equity
3,535,506
BB yield
-5.51%
Debt
Debt current
147,000
182,000
455,673
Long-term debt
2,042,000
2,127,000
2,136,239
Deferred revenue
27,542
Other long-term liabilities
72,000
45,000
10,541
Net debt
1,269,000
1,695,000
1,912,594
Cash flow
Cash from operating activities
757,000
636,000
384,306
CAPEX
(67,000)
(87,000)
(62,448)
Cash from investing activities
(124,000)
(144,000)
(6,518,495)
Cash from financing activities
(300,000)
(582,000)
5,748,703
FCF
356,000
229,828
120,234
Balance
Cash
861,000
578,000
630,094
Long term investments
59,000
36,000
49,224
Excess cash
744,400
452,300
595,278
Stockholders' equity
(821,000)
3,196,000
1,796,897
Invested Capital
15,705,000
18,530,700
17,239,680
ROIC
2.89%
2.75%
3.38%
ROCE
3.98%
3.16%
2.26%
EV
Common stock shares outstanding
135,395
135,395
114,625
Price
194.70
4.56%
186.20
-66.75%
560.00
159.50%
Market cap
26,361,333
4.56%
25,210,478
-60.73%
64,190,032
174.02%
EV
27,631,333
26,909,478
66,121,321
EBITDA
1,058,000
1,031,000
536,813
EV/EBITDA
26.12
26.10
123.17
Interest
94,000
44,000
10,364
Interest/NOPBT
14.85%
6.93%
2.42%